• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于胆固醇管理的功能性食品:作用机制、功效及新型降胆固醇能力指数综述

Functional Foods for Cholesterol Management: A Review of the Mechanisms, Efficacy, and a Novel Cholesterol-Lowering Capacity Index.

作者信息

Jacobo-Velázquez Daniel A

机构信息

Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Campus Monterrey, Av. Eugenio Garza Sada 2501 Sur, Monterrey 64849, NL, Mexico.

出版信息

Nutrients. 2025 Aug 15;17(16):2648. doi: 10.3390/nu17162648.

DOI:10.3390/nu17162648
PMID:40871675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12389712/
Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide, with elevated low-density lipoprotein cholesterol (LDL-C) as a major risk factor. Beyond medications, dietary interventions and functional foods offer significant cholesterol-lowering potential. This article provides a comprehensive review of functional foods and nutraceutical ingredients that help to reduce cholesterol levels and introduces the novel Cholesterol-Lowering Capacity Index (CLCI), designed to quantify and communicate the efficacy of such foods. In doing so, it summarizes key functional components, including plant sterols/stanols, viscous fibers, soy protein, red yeast rice, berberine, polyphenols (e.g., bergamot extract, garlic), and others, highlighting their mechanisms of action and the typical LDL-C reductions observed in clinical studies. Strategies for the design of next-generation cholesterol-lowering foods are discussed, such as combining multiple bioactives for synergistic effects, personalized nutrition approaches, and novel food processing techniques to enhance bioavailability. Building on these strategies, the CLCI is then proposed as a practical scoring system, analogous to the glycemic index for blood sugar, that integrates the evidence-based potency of ingredients, effective dosing, and synergistic interactions into a single metric. A methodology for the calculation of the CLCI is presented, alongside potential applications in food labeling, clinical guidance, and dietary planning.

摘要

心血管疾病(CVD)仍然是全球主要的死因,低密度脂蛋白胆固醇(LDL-C)升高是主要风险因素。除药物治疗外,饮食干预和功能性食品具有显著的降低胆固醇潜力。本文全面综述了有助于降低胆固醇水平的功能性食品和营养成分,并介绍了旨在量化和传达此类食品功效的新型降胆固醇能力指数(CLCI)。在此过程中,总结了关键功能成分,包括植物甾醇/甾烷醇、粘性纤维、大豆蛋白、红曲米、黄连素、多酚(如佛手柑提取物、大蒜)等,突出了它们的作用机制以及临床研究中观察到的LDL-C的典型降低情况。讨论了下一代降胆固醇食品的设计策略,如组合多种生物活性成分以产生协同效应、个性化营养方法以及提高生物利用度的新型食品加工技术。基于这些策略,CLCI随后被提议作为一种实用的评分系统,类似于血糖的血糖指数,将基于证据的成分效力、有效剂量和协同相互作用整合为一个单一指标。介绍了CLCI的计算方法,以及在食品标签、临床指导和饮食规划中的潜在应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d987/12389712/0a0359abd758/nutrients-17-02648-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d987/12389712/d40d65b45c6e/nutrients-17-02648-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d987/12389712/0a0359abd758/nutrients-17-02648-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d987/12389712/d40d65b45c6e/nutrients-17-02648-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d987/12389712/0a0359abd758/nutrients-17-02648-g002.jpg

相似文献

1
Functional Foods for Cholesterol Management: A Review of the Mechanisms, Efficacy, and a Novel Cholesterol-Lowering Capacity Index.用于胆固醇管理的功能性食品:作用机制、功效及新型降胆固醇能力指数综述
Nutrients. 2025 Aug 15;17(16):2648. doi: 10.3390/nu17162648.
2
The effect of oat β-glucan on LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a systematic review and meta-analysis of randomised-controlled trials.燕麦β-葡聚糖对降低心血管疾病风险的低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B的影响:一项随机对照试验的系统评价和荟萃分析
Br J Nutr. 2016 Oct;116(8):1369-1382. doi: 10.1017/S000711451600341X. Epub 2016 Oct 11.
3
Cholesterol-lowering efficacy of plant sterols/stanols provided in capsule and tablet formats: results of a systematic review and meta-analysis.植物甾醇/甾烷醇以胶囊和片剂形式提供的降胆固醇功效:系统评价和荟萃分析的结果。
J Acad Nutr Diet. 2013 Nov;113(11):1494-1503. doi: 10.1016/j.jand.2013.07.006.
4
Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis.植物甾醇/甾烷醇降低家族性高胆固醇血症患者的胆固醇浓度:一项系统评价与荟萃分析
J Am Coll Nutr. 2006 Feb;25(1):41-8. doi: 10.1080/07315724.2006.10719513.
5
Dietary interventions (plant sterols, stanols, omega-3 fatty acids, soy protein and dietary fibers) for familial hypercholesterolaemia.针对家族性高胆固醇血症的饮食干预措施(植物甾醇、甾烷醇、ω-3脂肪酸、大豆蛋白和膳食纤维)。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD001918. doi: 10.1002/14651858.CD001918.pub3.
6
Dietary fibre for the primary prevention of cardiovascular disease.膳食纤维用于心血管疾病的一级预防。
Cochrane Database Syst Rev. 2016 Jan 7;2016(1):CD011472. doi: 10.1002/14651858.CD011472.pub2.
7
PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.PCSK9 抑制剂和依折麦布降低心血管事件风险的临床实践指南:基于风险分层的推荐意见。
BMJ. 2022 May 4;377:e069066. doi: 10.1136/bmj-2021-069066.
8
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
9
The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis.植物甾醇和甾烷醇对血脂的比较疗效:一项系统评价和荟萃分析。
J Am Diet Assoc. 2010 May;110(5):719-26. doi: 10.1016/j.jada.2010.02.011.
10
Fixed-dose combination therapy for the prevention of cardiovascular disease.用于预防心血管疾病的固定剂量复方疗法。
Cochrane Database Syst Rev. 2014 Apr 16;4(4):CD009868. doi: 10.1002/14651858.CD009868.pub2.

本文引用的文献

1
Apolipoprotein E Genetic Variant and Blood Lipid Responses to Plant Sterols: A Systematic Review and Pooled Analysis of Clinical Trials.载脂蛋白E基因变异与植物甾醇的血脂反应:一项临床试验的系统评价与汇总分析
Prev Nutr Food Sci. 2023 Dec 31;28(4):377-385. doi: 10.3746/pnf.2023.28.4.377.
2
Plant Sterols and Plant Stanols in Cholesterol Management and Cardiovascular Prevention.植物甾醇和植物固醇在胆固醇管理和心血管预防中的作用。
Nutrients. 2023 Jun 22;15(13):2845. doi: 10.3390/nu15132845.
3
Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials.
ω-3 脂肪酸摄入与血脂异常的关系:一项随机对照试验的连续剂量反应荟萃分析。
J Am Heart Assoc. 2023 Jun 6;12(11):e029512. doi: 10.1161/JAHA.123.029512. Epub 2023 Jun 2.
4
Functional foods and nutraceuticals in the treatment of hypercholesterolemia: Statement of the Spanish Society of Arteriosclerosis 2023.功能性食品和营养保健品在高胆固醇血症治疗中的作用:西班牙动脉粥样硬化学会 2023 年声明。
Clin Investig Arterioscler. 2023 Sep-Oct;35(5):248-261. doi: 10.1016/j.arteri.2023.02.002. Epub 2023 Mar 15.
5
The effect of bergamot (KoksalGarry) supplementation on lipid profiles: A systematic review and meta-analysis of randomized controlled trials.补充佛手柑(KoksalGarry)对血脂水平的影响:一项随机对照试验的系统评价和荟萃分析。
Phytother Res. 2022 Dec;36(12):4409-4424. doi: 10.1002/ptr.7647. Epub 2022 Oct 17.
6
Replacing saturated fatty acids with polyunsaturated fatty acids increases the abundance of Lachnospiraceae and is associated with reduced total cholesterol levels-a randomized controlled trial in healthy individuals.用多不饱和脂肪酸替代饱和脂肪酸会增加厚壁菌门的丰度,并与总胆固醇水平降低相关:一项健康个体的随机对照试验。
Lipids Health Dis. 2022 Sep 26;21(1):92. doi: 10.1186/s12944-022-01702-1.
7
Fermented Foods, Health and the Gut Microbiome.发酵食品、健康与肠道微生物组。
Nutrients. 2022 Apr 6;14(7):1527. doi: 10.3390/nu14071527.
8
Reduction in Serum LDL Cholesterol Using a Nutrient Compendium in Hyperlipidemic Adults Unable or Unwilling to Use Statin Therapy: A Double-Blind Randomized Crossover Clinical Trial.降脂营养补充剂用于他汀类药物不耐受或不愿意使用的高脂血症患者的血清 LDL 胆固醇降低:一项双盲随机交叉临床试验。
J Nutr. 2022 Feb 8;152(2):458-465. doi: 10.1093/jn/nxab375.
9
The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.小檗碱对 2 型糖尿病患者代谢谱的影响:系统评价和随机对照试验的荟萃分析。
Oxid Med Cell Longev. 2021 Dec 15;2021:2074610. doi: 10.1155/2021/2074610. eCollection 2021.
10
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?营养保健品在血脂异常管理中的应用:何时、何地、何人适用?营养保健品能否帮助血脂水平非最佳的低危个体?
Curr Atheroscler Rep. 2021 Aug 4;23(10):57. doi: 10.1007/s11883-021-00955-y.